Novel chemical compound SINCRO with dual function in STING‐type I interferon and tumor cell death pathways

Recent years have seen a number of regulatory approvals for immune oncology or immunotherapies based on their ability to enhance antitumor immune responses. Nevertheless, the majority of patients remain refractory to these treatments; hence, new therapies that augment current immunotherapies are req...

Descripción completa

Detalles Bibliográficos
Autores principales: Kimura, Yoshitaka, Negishi, Hideo, Matsuda, Atsushi, Endo, Nobuyasu, Hangai, Sho, Inoue, Asuka, Nishio, Junko, Taniguchi, Tadatsugu, Yanai, Hideyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125434/
https://www.ncbi.nlm.nih.gov/pubmed/29981256
http://dx.doi.org/10.1111/cas.13726

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6125434/
https://www.ncbi.nlm.nih.gov/pubmed/29981256
http://dx.doi.org/10.1111/cas.13726

Ejemplares similares